title: Donor cell-derived sarcoidosis after allogeneic BMT.
authors.forename: R
authors.initials: R
authors.lastname: Morita
authors.forename: S
authors.initials: S
authors.lastname: Hashino
authors.forename: K
authors.initials: K
authors.lastname: Kubota
authors.forename: M
authors.initials: M
authors.lastname: Onozawa
authors.forename: K
authors.initials: K
authors.lastname: Kahata
authors.forename: T
authors.initials: T
authors.lastname: Kondo
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuno
authors.forename: M
authors.initials: M
authors.lastname: Imamura
authors.forename: M
authors.initials: M
authors.lastname: Asaka
mesh_terms: D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000494:pharmacology; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008224:Lymphoma, Follicular / Q000150:complications / Q000628:therapy; D008875:Middle Aged; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000494:pharmacology; D012074:Remission Induction; D012507:Sarcoidosis / Q000209:etiology*; D014184:Transplantation, Homologous / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18